

Гл. Ас. д-р Даниел Валентинов Йорданов

Служебен телефон: +359 2 9172780

Email: dr.daniel.yordanov.md@gmail.com

Служебен email: yordanov_dv@medfac.mu-sofia.bg

Снимка:



Длъжност: Главен асистент

Административен асистент

2009 г придобита специалност

2017 г защитена дисертация

на тема:

"*Helicobacter pylori* - фактори на вирулентност, антиминокробна резистентност и серопревалиране"

Научни интереси:

Молекулярни методи

серологични методи

фактори на вирулентност и резистентност на *Helicobacter pylori* и на анаеробни бактерии

Публикации в списания с импакт фактор

Strateva T, **Yordanov D**. Pseudomonas aeruginosa—a phenomenon of bacterial resistance. Journal of medical microbiology. 2009;58(9):1133-48. (IF2009 = 2.046)

Boyanova L, Markovska R, **Yordanov D**, Marina M, Ivanova K, Panayotov S, Gergova G, Mitov I. High prevalence of virulent Helicobacter pylori strains in symptomatic Bulgarian patients. Diagnostic microbiology and infectious disease. 2009;64(4):374-80. (IF2009 = 2.919)

Boyanova L, **Yordanov D**, Gergova G, Markovska R, Mitov I. Association of iceA and babA genotypes in Helicobacter pylori strains with patient and strain characteristics. Antonie Van Leeuwenhoek. 2010;98(3):343-50. (IF2010 = 2.041)

Boyanova L, **Yordanov D**, Gergova G, Markovska R, Mitov I. Benefits of Helicobacter pylori cagE genotyping in addition to cagA genotyping: a Bulgarian study. Antonie Van Leeuwenhoek. 2011;100(4):529-35. (IF2011 = 2.366)

Markovska R, Boyanova L, **Yordanov D**, Gergova G, Mitov I. Helicobacter pylori oipA genetic diversity and its associations with both disease and cagA, vacA s, m, and i alleles among Bulgarian patients. Diagnostic microbiology and infectious disease. 2011;71(4):335-40. (IF2011 = 2.906)

Yordanov D, Boyanova L, Markovska R, Gergova G, Mitov I. Significance of Helicobacter pylori vacA intermediate region genotyping—a Bulgarian study. Diagnostic microbiology and infectious disease. 2012;74(3):253-7. (IF2012 = 2.753)

Boyanova L, Panov V, **Yordanov D**, Gergova G, Mitov I. Characterization of oral Helicobacter pylori strain by 4 methods. Diagnostic microbiology and infectious disease. 2013;77(4):287-8. (IF2013 = 2.981)

Boyanova L, Markovska R, **Yordanov D**, Gergova G, Mitov I. Clarithromycin resistance mutations in Helicobacter pylori in association with virulence factors and antibiotic susceptibility of the strains. Microb Drug Resist. 2016; 22(3): 227-232. (IF2016 2,306)

Boyanova L, Evstatiev I, **Yordanov D**, Markovska R, Mitov I. Three unsuccessful treatments of Helicobacter pylori infection by a highly virulent strain with quadruple antibiotic resistance. Folia Microbiol (Praha). 2016; 61(4): 307-310. (IF2016 1,521)

Yordanov D, Boyanova L, Markovska R, Ilieva J, Andreev N, Gergova G, Mitov I. Helicobacter pylori seroprevalence in Bulgaria over 18 years and anti-CagA seroprevalence. C R AcadBulg Sci. 2016; 69(12): 1651-1658. (IF2016 0,251)

Yordanov D, Boyanova L, Markovska RD, Ilieva J, Andreev N, Gergova G, Mitov IG. Influence of dietary factors on Helicobacter pylori and CagA seroprevalence in Bulgaria. Gastroenterol Res Pract. 2017; 2017: Article ID 9212143, doi:10.1155/2017/9212143 <https://www.hindawi.com/journals/grp/2017/9212143/> (IF2016 1,863)

Boyanova L, Gergova G, Markovska R, **Yordanov D**, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. *Lett Appl Microbiol*. 2017;65(6): 469-474. (IF2016 1,575)

Markovska R, Boyanova L, **Yordanov D**, Stankova P, Gergova G, Mitov I. Status of *Helicobacter pylori* cag pathogenicity island (cagPAI) integrity and significance of its individual genes. *Infect Genet Evol*. 2018; 59: 167-171. (IF2016 2,885)

Boyanova L, Koumanova R, Hadzhiyski P, Gergova G, Markovska R, **Yordanov D**, Mitov I. *Helicobacter pylori* infection in Bulgarian pediatric patients. *C R AcadBulg Sci*. 2018; 71(7): 971-977. (IF2017 0,270)

Yordanov D, Boyanova L, Markovska R, Hadzhiyski P, Gergova G, Mitov I. Seroprevalence of *Helicobacter pylori* IgG and CagA IgG in Bulgarian children. *C R AcadBulg Sci*. 2018; 71(8): 1124-1129. (IF2017 0,270)

Boyanova L, Hadzhiyski P, Markovska R, Yaneva P, **Yordanov D**, Gergova G, Mitov I. Prevalence of *Helicobacter pylori* is still high among symptomatic Bulgarian children. *Acta Microbiol Immunol Hung*. 2019; 66(2): 255-260. (IF2017 1,107)

Boyanova L, Markovska R, Hadzhiyski P, **Yordanov D**, Yaneva P, Mitov I. Recurrent *Clostridioides (Clostridium) difficile* infection in a patient suffering from inflammatory bowel disease and benefits of resistotyping. *Diagn Microbiol Infect Dis*. 2019; 94(4): 334-336. (IF2017 2,341)

Boyanova L, Kalvatchev N, **Yordanov D**, Hadzhiyski P, Markovska R, Gergova G, Mitov I. *Clostridioides (Clostridium) difficile* carriage in asymptomatic children since 2010: a narrative review. *Biotechnol Biotec Eq*. 2019; 33 (1): 1228-1236. (IF2018 1,227)

Boyanova L, **Yordanov D**, Ouzounova-Raykova V, Markovska R, Marteva-Proevska Y, Mitov I. Activity of delafloxacin versus that of levofloxacin against anaerobic and microaerophilic isolates. *Anaerobe*. 2020; 62: 102150. (IF2018 2,704)

Boyanova L, Marteva-Proevska Y, Markovska R, **Yordanov D**, Gergova R. Urinary tract infections: Should we think about the anaerobic cocci?. *Anaerobe*. 2022:102509.(IF 3,331)